Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BSE - Free Realtime Quote INR

Mangalam Drugs & Organics Limited (MANGALAM.BO)

Compare
76.42
0.00
(0.00%)
As of April 11 at 3:15:57 PM GMT+5:30. Market Open.
Loading Chart for MANGALAM.BO
  • Previous Close 76.42
  • Open 80.00
  • Bid 79.09 x --
  • Ask 79.48 x --
  • Day's Range 75.41 - 80.00
  • 52 Week Range 70.11 - 144.65
  • Volume 755
  • Avg. Volume 6,232
  • Market Cap (intraday) 1.21B
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) 11.87
  • EPS (TTM) 6.44
  • Earnings Date Feb 13, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 21, 2017
  • 1y Target Est --

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers API products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; and ortho phenoxy methane sulfonanilide, tenofovir alafenamide base, and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol; bictegravir Na, aripiprazole, risperidone, olanzapine, and etodolac; and develops tafenoquine succinate and pretomanid. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. The company was incorporated in 1972 and is based in Mumbai, India.

www.mangalamdrugs.com

432

Full Time Employees

March 31

Fiscal Year Ends

Recent News: MANGALAM.BO

View More

Performance Overview: MANGALAM.BO

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

MANGALAM.BO
33.78%
S&P BSE SENSEX (^BSESN)
1.73%

1-Year Return

MANGALAM.BO
22.41%
S&P BSE SENSEX (^BSESN)
4.62%

3-Year Return

MANGALAM.BO
36.82%
S&P BSE SENSEX (^BSESN)
31.63%

5-Year Return

MANGALAM.BO
79.81%
S&P BSE SENSEX (^BSESN)
152.76%

Compare To: MANGALAM.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MANGALAM.BO

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    1.21B

  • Enterprise Value

    1.87B

  • Trailing P/E

    11.87

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.35

  • Price/Book (mrq)

    0.82

  • Enterprise Value/Revenue

    0.54

  • Enterprise Value/EBITDA

    5.48

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.94%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    3.47B

  • Net Income Avi to Common (ttm)

    101.91M

  • Diluted EPS (ttm)

    6.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    60.86M

  • Total Debt/Equity (mrq)

    67.20%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: MANGALAM.BO

View More

Company Insights: MANGALAM.BO

Research Reports: MANGALAM.BO

View More

People Also Watch